Tissue-engineered model developed to study bone-invading tumor
New Rochelle, NY, February 24, 2017–Researchers have used tissue engineering to create models for studying the bone-destroying activity of tumors such as the aggressive pediatric cancer Ewing’s sarcoma. A new 3-dimensional, living model of the osteolytic process and bone remodeling, which can serve a valuable tool for exploring disease mechanisms and the effectiveness of potential treatments, is described in Tissue Engineering, Part C, Methods, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Tissue Engineering website until March 24, 2017.
In the article entitled “Tissue-Engineered Model of Human Osteolytic Bone Tumor,” Gordana Vunjak-Novakovic and coauthors from Columbia University, New York, NY and Politecnico di Milano, Italy, present the methods used to bioengineer a living Ewing’s sarcoma model that includes both osteoclasts and osteoblasts in a controllable biomimetic environment. The researchers demonstrate the usefulness of the model for testing anti-osteolytic drugs.
“There is an urgent need for the development of human-like tumor models. This article is an excellent example of the progress being made,” says Methods Co-Editor-in-Chief John A. Jansen, DDS, PhD, Professor and Head, Department of Biomaterials, Radboud University Medical Center, The Netherlands.
Research reported in this publication was supported by the National Institutes of Health under Award Numbers EB002520 and EB17103. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Principal, MedSurgPI, LLC, President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed online at the Tissue Engineering website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.